Serum IGF-BP2 strongly moderates age's effect on cognition: A MIMIC analysis

Neurobiology of Aging

Volumn 36, Issue 7, 2015, Pages 2232-2240

  Royall, Donald R ^a,b,c   Bishnoi, Ram J ^a   Palmer, Raymond F ^b  

^a Mays Cancer Center at UT Health San Antonio   (United States)

^b UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^c SOUTH TEXAS VETERANS HEALTH CARE SYSTEM   (United States)

Author keywords

Aging; Biomarkers; Cognition; G; IGF BP2; Intelligence

Indexed keywords

APOLIPOPROTEIN E4; HEMOGLOBIN A1C; HOMOCYSTEINE; SOMATOMEDIN BINDING PROTEIN 2;

ADULT; AGE; ALZHEIMER DISEASE; AREA UNDER THE CURVE; ARTICLE; CLINICAL DEMENTIA RATING SCALE; COGNITION; COGNITIVE CORRELATES OF AGE; COGNITIVE DEFECT; COMPARATIVE STUDY; CONTROLLED STUDY; DEMENTIA; DISEASE SEVERITY; EDUCATIONAL STATUS; ETHNICITY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MATHEMATICAL PARAMETERS; MIDDLE AGED; MULTIPLE INDICATORS MULTIPLE CAUSES MODEL; PREDICTIVE VALUE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN FUNCTION; RATING SCALE; RECEIVER OPERATING CHARACTERISTIC; SENSITIVITY AND SPECIFICITY; STRUCTURAL EQUATION MODELING; AGED; AGING; ATROPHY; BLOOD; BRAIN CORTEX; GENETICS; PATHOLOGY; PHYSIOLOGY; PSYCHOLOGY; STATISTICAL MODEL; VERY ELDERLY;

AGED; AGED, 80 AND OVER; AGING; ATROPHY; CEREBRAL CORTEX; COGNITION; COGNITION DISORDERS; FEMALE; HUMANS; INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN 2; MALE; MODELS, STATISTICAL;

EID: 84930074893     PISSN: 01974580     EISSN: 15581497     Source Type: Journal    
DOI: 10.1016/j.neurobiolaging.2015.04.003     Document Type: Article

References (61)

1. Aleman A., Verhaar H.J.J., de Haan E.H.F., de Vries W.R., Samson M.M., Drent M.L., van der Veen E.A., Koppeschaar H.P.F. Insulin-like growth factor-I and cognitive function in healthy older men. J. Clin. Endocrinol. Metab. 1999, 84:471-475.
2. Arbuckle J.L. Analysis of Moment Structures-amos (Version 7.0) [Computer Program] 2006, SPSS, Chicago.
3. Bentler P.M. Comparative fit indexes in structural models. Psychol. Bull. 1990, 107:238-246.
4. Benton A., Hamsher K. Multilingual Aphasia Examination 1989, AJA Associates, Iowa City, Iowa.
5. Berryman D.E., Christiansen J.S., Johannsson G., Thorner M.O., Kopchick J.J. Role of GH/IGF-I axis in lifespan and healthspan: lessons from animal models. Growth Horm. IGF Res. 2008, 18:455-471.
6. Bishnoi R., Palmer R.F., Royall D.R. Vitamin d binding protein as a serum biomarker of Alzheimer disease. J. Alzheimers Dis. 2015, 43:37-45.
7. Bishnoi R., Palmer R.F., Royall D.R. IL-15 as a serum biomarker of Alzheimer disease. PLoS One 2015, 10:e0117282.
8. Bollen K.A., Long J.S. Testing Structural Equation Models 1993, Sage Publications, Thousand Oaks, CA.
9. Breese C.R., D'Costa A., Rollins Y.D., Adams C., Booze R.M., Sonntag W.E., Leonard S. Expression of insulin-like growth factor-1 (IGF-1) and IGF-binding protein 2 (IGF-BP2) in the hippocampus following cytotoxic lesion of the dentate gyrus. J. Comp. Neurol. 1996, 369:388-404.
10. Browne M., Cudeck R. Alternative ways of assessing model fit. Testing Structural Equation Models 1993, 136-162. Sage Publications, Thousand Oaks, CA. K.A. Bollen, J.S. Long (Eds.).
11. Carro E., Trejo J.L., Gomez-Isla T., LeRoith D., Torres-Aleman I. Serum insulin-like growth factor I regulates brain amyloid-beta levels. Nat. Med. 2002, 8:1390-1397.
12. Chelune G.J., Duff K. The assessment of change: serial assessments in dementia evaluations. Handbook on the Neuropsychology of Aging and Dementia Clinical Handbooks in Neuropsychology 2013, 43-57. Springer, New York, 2013. L.D. Ravdin, H.L. Katzen (Eds.).
13. Chen D.Y., Stern S.A., Garcia-Osta A., Saunier-Rebori B., Pollonini G., Bambah-Mukku D., Blitzer R.D., Alberini C.M. A critical role for IGF-II in memory consolidation and enhancement. Nature 2011, 469:491-497.
14. Crary J.F., Trojanowski J.Q., Schneider J.A., Abisambra J.F., Abner E.L., Alafuzoff I., Arnold S.E., Attems J., Beach T.G., Bigio E.H., Cairns N.J., Dickson D.W., Gearing M., Grinberg L.T., Hof P.R., Hyman B.T., Jellinger K., Jicha G.A., Kovacs G.G., Knopman D.S., Kofler J., Kukull W.A., Mackenzie I.R., Masliah E., McKee A., Montine T.J., Murray M.E., Neltner J.H., Santa-Maria I., Seeley W.W., Serrano-Pozo A., Shelanski M.L., Stein T., Takao M., Thal D.R., Toledo J.B., Troncoso J.C., Vonsattel J.P., White C.L., Wisniewski T., Woltjer R.L., Yamada M., Nelson P.T. Primary age-related tauopathy (PART): a common pathology associated with human aging. Acta Neuropathol. 2014, 128:755-766.
15. de la Monte S.M., Wands J.R. Review of insulin and insulin-like growth factor expression, signaling, and malfunction in the central nervous system: relevance to Alzheimer's disease. J. Alzheimers Dis. 2005, 7:45-61.
16. Firth S.M., Baxter R.C. Cellular actions of the insulin-like growth factor binding proteins. Endocr. Rev. 2002, 23:824-854.
17. Folstein M.F., Folstein S.E., McHugh P.R. Mini-mental state: a practical method for grading the cognitive state of patients for the clinician. J. Psychiatry Res. 1975, 12:189-198.
18. Gavett B.E., Vudy V., Jeffrey M., John S.E., Gurnani A., Adams J. The δ latent dementia phenotype in the NACC UDS: cross-validation and extension. Neuropsychology 2015, 29:344-352.
19. Gavett B.E. Neuropathology mediates age, race, and APOE effectson d in pathologically confirmed AD. Abstract Presented at: 43rd AnnualMeeting of the International Neuropsychological Society. February 6, 2015 2015, Colorado, Denver.
20. Graham J.W. Missing data analysis: making it work in the real world. Ann. Rev. Psychol. 2009, 6:549-576.
21. Grober E., Sliwinski M. Development and validation of a model for estimating premorbid verbal intelligence in the elderly. J. Clin. Exp. Neuropsychol. 1991, 13:933-949.
22. Hoffman A.R., Pyka G., Lieberman S.A., Ceda G.P., Marcus R. The somatopause. Growth Hormone and Somatomedins during Lifespan 1993, Springer Verlag, Berlin. E.E. Muller, D. Cocchi, V. Locatelli (Eds.).
23. Hu D., Pawlikowska L., Kanaya A., Huseh W.-C., Colbert L., Newman A.B., Satterfield S., Rosen C., Cummings S.R., Harris T.B., Ziv E. Serum insulin-like growth factor-1 binding proteins 1 and 2 and mortality in older adults: the health, aging, and body composition study. J. Am. Geriatr. Soc. 2009, 57:1213-1218.
24. Hughes C.P., Berg L., Danziger W.L., Coben L.A., Martin R.L. A new clinical scale for the staging of dementia. Br. J. Psychiatry 1982, 140:566-572.
25. Hwa V., Oh Y., Rosenfeld R.G. The insulin-like growth factor-binding protein (IGFBP) superfamily. Endocr. Rev. 1999, 20:761-787.
26. Kaplan E.F., Goodglass H., Weintraub S. The Boston Naming Test. Experimental Edition. Boston: Kaplan & Goodglass 1983, Lea & Febiger, Philadelphia. second ed.
27. Kar S., Chabot J.G., Quirion R. Quantitative autoradiographic localization of [125I]insulin-like growth factor I, [125I]insulin-like growth factor II, and [125I]insulin receptor binding sites in developing and adult rat brain. J. Comp. Neurol. 1993, 333:375-397.
28. Kitraki E., Bozas E., Philippidis H., Stylianopoulou F. Aging-related changes in IGF-II and c-fos gene expression in the rat brain. Int. J. Dev. Neurosci. 1993, 11:1-9.
29. Koch W., Ehrenhaft A., Griesser K., Pfeufer A., Muller J., Schomig A., Kastrati A. TaqMan systems for genotyping of disease-related polymorphisms present in the gene encoding apolipoprotein E. Clin. Chem. Lab. Med. 2002, 40:1123-1131.
30. Le Roith D. The insulin-like growth factor system. Exp. Diabesity Res. 2003, 4:205-212.
31. Liu X., Yao D.-L., Bondy C.A., Brenner M., Hudson L.D., Zhou J., Webster H.dF. Astrocytes express insulin-like growth factor-I (IGF-I) and its binding protein, IGFBP-2, during demyelination induced by experimental autoimmune encephalomyelitis. Mol. Cell. Neurosci. 1994, 5:418-430.
32. Mattsson A., Svensson D., Schuett B., Osterziel K.J., Ranke M.B. Multidimensional reference regions for IGF-I, IGFBP-2 and IGFBP-3 concentrations in serum of healthy adults. Growth Horm. IGF Res. 2008, 18:506-516.
33. McKhann G., Drachman D., Folstein M., Katzman R., Price D., Stadlan E.M. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group. Neurology 1984, 34:939-944.
34. Maixner S.M., Burke W.J., Roccaforte W.H., Wengel S.P., Potter J.F. A comparison of two depression scales in a geriatric assessment clinic. Am. J. Geriatr. Psychiatry 1995, 3:60-67.
35. Metz C.E. Basic principles of ROC analysis. Semin Nucl Med. 1978, 8:283-298.
36. Muthén B.O. Dichotomous factor analysis of symptom data. Sociological Methods Res. 1989, 18:19-65.
37. Muthén B., Tam T., Muthén L., Stolzenberg R., Hollis M. Latent variable modeling in the LISCOMP framework: measurement of attitudes towards career choice. New Directions in Attitude Measurement 1993, 277-290. Walter de Gruyter, Berlin, Germany. D. Krebs, P. Schmidt (Eds.).
38. Nelson P.T., Head E., Schmitt F.A., Davis P.R., Neltner J.H., Jicha G.A., Abner E.L., Smith C.D., Van Eldik L.J., Kryscio R.J., Scheff S.W. Alzheimer's disease is not "brain aging": neuropathological, genetic, and epidemiological human studies. Acta Neuropathol. 2011, 121:571-587.
39. Oh Y., Müller H.L., Lee D.Y., Fielder P.J., Rosenfeld R.G. Characterization of the affinities of insulin-like growth factor (IGF)-binding proteins 1-4 for IGF-I,IGF-II, IGF-I/insulin hybrid, and IGF-I analogs. Endocrinology 1993, 132:1337-1344.
40. Palmer R., Royall D.R. Missing data? Plan on it!. J. Am. Geriatr. Soc. 2010, 58:S343-S348.
41. PASW Statistics 18, Release Version 18.0.0 2009, SPSS, Inc., Chicago, IL.
42. Reitan R.M. Validity of the Trail Making Test as an indicator of organic brain damage. Percept. Mot. Skills 1958, 8:271-276.
43. Reitz C., Mayeux R. Alzheimer disease: epidemiology, diagnostic criteria, risk factors and biomarkers. Biochem. Pharmacol. 2014, 88:640-651.
44. Royall D.R., Palmer R.F. Validation of a latent construct for dementia case-finding in Mexican-Americans. J. Alzhemiers Dis. 2013, 37:89-97.
45. Royall D.R., Palmer R.F. Does ethnicity moderate dementia's biomarkers?. Neurobiol. Aging 2014, 35:336-344.
46. Royall D.R., Palmer R.F. Ethnicity moderates Dementia's biomarkers. J. Alzheimers Dis. 2015, 43:275-287.
47. Royall D.R., Palmer R.F., O'Bryant S.E. Validation of a latent variable representing the dementing process. J. Alzheimers Dis. 2012, 30:639-649.
48. Royall D.R., Palmer R.F., Vidoni E.D., Honea R.A., Burns J.M. The default mode network and related right hemisphere structures may be the key substrates of dementia. J. Alzheimers Dis. 2012, 32:467-478.
49. Royall D.R., Palmer R.F., Vidoni E.D., Honea R.A. The default mode network may be the key substrate of depression related cognitive changes. J. Alzheimers Dis. 2013, 34:547-560.
50. Russo V.C., Gluckman P.D., Feldman E.L., Werther G.A. The insulin-like growth factor system and its pleiotropic functions in brain. Endocr. Rev. 2005, 26:916-943.
51. Sárvári M., Kalló I., Hrabovszky E., Solymosi N., Tóth K., Likó I., Molnár B., Tihanyi K., Liposits Z. Estradiol replacement alters expression of genes related to neurotransmission and immune surveillance in the frontal cortex of middle-aged, ovariectomized rats. Endocrinology 2010, 151:3847-3862.
52. Schafer J.L., Graham J.W. Missing data: our view of the state of the art. Psychol. Methods 2002, 7:147-177.
53. Spearman C., Jones L.L.W. Human Ability 1951, Macmillan & Co., London.
54. Toledo J.B., Da X., Bhatt P., Wolk D.A., Arnold S.E., Shaw L.M., Trojanowski J.Q., Davatzikos C. Relationship between plasma analytes and SPARE-AD defined brain atrophy patterns in ADNI. PLoS One 2013, 8:e55531. Alzheimer's Disease Neuroimaging Initiative.
55. van den Beld A.W., Blum W.F., Pols H.A., Grobbee D.E., Lamberts S.W. Serum insulin-like growth factor binding protein-2 levels as an indicator of functional ability in elderly men. Eur. J. Endocrinol. 2003, 148:627-634.
56. Waring S., O'Bryant S.E., Reisch J.S., Diaz-Arrastia R., Knebl J., Doody R. The Texas Alzheimer's Research Consortium longitudinal research cohort: study design and baseline characteristics. Texas Pub Health J 2008, 60:9-13. for the Texas Alzheimer's Research Consortium.
57. Wechsler D. Wechsler Memory Scale - Third Edition 1997, The Psychological Corporation, San Antonio, TX.
58. Wheaton B., Muthén B., Alwin D.F., Summer G.F. Assessing reliability and stability in panel models. Sociology Methodology 1977, Jossey-Bass, San Francisco, CA. D.R. Heise (Ed.).
59. Wood T.L., Rogler L.E., Czick M.E., Schuller A.G.P., Pintar J.E. Selective alterations in organ sizes in mice with a targeted disruption of the insulin-like growth factor binding protein-2 gene. Mol. Endocrinol. 2000, 14:1472-1482.
60. Yesavage J.A., Brink T.L., Rose T.L., Lum O., Huang V., Adey M., Leirer V.O. Development and validation of a geriatric depression screening scale: a preliminary report. J. Am. Geriatr. Soc. 1982, 29:164-171.
61. Zweig M.H., Campbell G. Receiver-operating characteristic (ROC) plots: a fundamental evaluation tool in clinical medicine. Clin. Chem. 1993, 39:561-577.